Galmed Pharmaceuticals (GLMD) Convertible Debt (2022 - 2025)
Galmed Pharmaceuticals (GLMD) posted quarterly Convertible Debt of $3.7 million for Q4 2025, down 3.07% year-over-year from $3.8 million in Q4 2024, and down 3.07% quarter-over-quarter from $3.8 million in Q4 2024.
Galmed Pharmaceuticals (GLMD) Convertible Debt (2022 - 2025) Analysis & Trends
Galmed Pharmaceuticals' Convertible Debt history runs 4 years deep, the most recent figure standing at $3.7 million for Q4 2025.
- In Q4 2025, Convertible Debt fell 3.07% year-over-year to $3.7 million; the TTM figure through Dec 2025 stood at $3.7 million (down 3.07% YoY), while the FY2025 annual figure was $3.7 million, down 3.07% from the prior year.
- Convertible Debt for Q4 2025 stood at $3.7 million, down from $3.8 million in the prior quarter.
- The five-year high for Convertible Debt was $4.4 million in Q1 2023, with the low at $3.7 million in Q4 2025.
- The 4-year median for Convertible Debt is $4.0 million (2022), against an average of $4.0 million.
- Peak annual rise in Convertible Debt reached 3.07% in 2025, while the deepest fall reached 3.07% in 2025.
- Galmed Pharmaceuticals' Convertible Debt stood at $4.1 million in 2022, then advanced by 8.83% to $4.4 million in 2023, then dropped by 13.6% to $3.8 million in 2024, then dropped by 3.07% to $3.7 million in 2025.
- Business Quant data shows GLMD's Convertible Debt at $3.7 million in Q4 2025, $3.8 million in Q4 2024, and $4.4 million in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Galmed Pharmaceuticals | 2.39 Mn | -9.49 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.73 Mn |
| Dec 31, 2024 | 3.85 Mn |
| Mar 31, 2023 | 4.45 Mn |
| Dec 31, 2022 | 4.09 Mn |